Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

Ramadan A. Ali1, Alex A. Gandhi1, He Meng1, Srilakshmi Yalavarthi1, Andrew P. Vreede1, Shanea K. Estes1, Olivia R. Palmer2, Paula L. Bockenstedt3, David J. Pinsky4,5, Joan M. Greve2, Jose A. Diaz6, Yogendra Kanthi5,7 & Jason S. Knight1

Potentiation of neutrophil extracellular trap (NET) release is one mechanism by which antiphospholipid antibodies (aPL Abs) effect thrombotic events in patients with antiphospholipid syndrome (APS). Surface adenosine receptors trigger cyclic AMP (cAMP) formation in neutrophils, and this mechanism has been proposed to regulate NETosis in some contexts. Here we report that selective agonism of the adenosine A2A receptor (CGS21680) suppresses aPL Ab-mediated NETosis in protein kinase A-dependent fashion. CGS21680 also reduces thrombosis in the inferior vena cavae of both control mice and mice administered aPL Abs. The antithrombotic medication dipyridamole is known to potentiate adenosine signaling by increasing extracellular concentrations of adenosine and interfering with the breakdown of cAMP. Like CGS21680, dipyridamole suppresses aPL Ab-mediated NETosis via the adenosine A2A receptor and mitigates venous thrombosis in mice. In summary, these data suggest an anti-inflammatory therapeutic paradigm in APS, which may extend to thrombotic disease in the general population.
Thrombotic events are among the leading causes of morbidity in patients with lupus. Antiphospholipid antibodies, present in one-third of lupus patients, are a major driver of this risk and help define a complication known as antiphospholipid syndrome (APS). Patients are classified as having APS when circulating antiphospholipid antibodies are detected in the setting of certain criteria-fulfilling events, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. The diagnosis of APS is not limited to patients with lupus and more than half of patients (53% in the largest study to date) are diagnosed as a standalone syndrome—primary APS. Overall, APS is felt to be the leading acquired cause of thrombosis in the United States. APS also places patients at increased risk for pregnancy loss, cytopenias, cardiac valve lesions, and neurologic complications. Patients with APS are typically treated with anticoagulants such as warfarin, which are not always effective in preventing thrombosis, and at the same time offer no protection against the varied non-thrombotic manifestations of APS, such as cardiac valve damage, thrombocytopenia, and cognitive decline. Interestingly, the best described antigen in APS is not a phospholipid, but rather a phospholipid-binding protein, beta-2 glycoprotein I (β2GPI). This cationic lipid-binding protein is made especially by the liver and is found in plasma at 50–200 µg ml⁻¹. While the pathophysiology of APS has yet to be fully elucidated, the prevailing opinion currently is that anti-β2GPI antibodies (and in some cases antibodies to other, similar phospholipid-binding proteins) potentiate thrombosis by engaging their antigen on cell surfaces, and thereby promoting the activation of endothelial cells, platelets, monocytes, and neutrophils.

Despite the abundance of human neutrophils (100 billion new cells produced each day), our knowledge of their role—and malleability—in chronic disease remains quite rudimentary. Our group has recently undertaken the study of neutrophils in patients with autoimmune thrombophilia, using APS as the model disease. We have revealed that the neutrophils of APS patients have a reduced threshold for the release of neutrophils extracellular traps (NETs)—prothrombotic tangles of DNA, histones, and granule-derived proteins expelled from dying neutrophils. We have also demonstrated that purified control neutrophils display β2GPI—a key APS autoantigen—on their surface, and can be triggered to release NETs in TLR4-dependent fashion by exposure to anti-β2GPI isolated from APS patients. Using a human/mouse chimeric model, we have shown that NETs are required for APS-potentiated thrombosis. By profiling the transcriptome of APS neutrophils, we have discovered a strikingly activated signature in APS neutrophils as compared with controls, which has revealed previously unconsidered therapeutic targets in APS such as P-selectin glycoprotein ligand-1 (PSGL-1).

Recent evidence suggests that the second messenger cyclic AMP (cAMP) may suppress NETosis in some contexts. Here, we hypothesized that surface adenosine receptors (which trigger cAMP formation in neutrophils) may serve as an endogenous counterpart to thromboinflammatory disease, and that pharmacological agonism of adenosine receptors may therefore mitigate the thrombotic manifestations of APS. Adenosine receptors vary in both affinity for adenosine and tissue/cell distribution. All four adenosine receptors have been described on neutrophils. The adenosine A1 receptor, which has a relatively high affinity for adenosine, promotes neutrophil chemotaxis. In contrast, the other three adenosine receptors, which may only become activated when the local environment is flooded with excess adenosine, tend to silence neutrophils. In particular, the A2A and A3 receptors are expressed at high levels on neutrophils, where they suppress neutrophil effector functions such as reactive oxygen species (ROS) formation when activated. A single study has demonstrated that agonism of the A2A receptor is protective against nephritis in a model of lupus, and work by our group has shown that deletion of the ectonucleotidase CD73 (which plays a key role in generating extracellular adenosine) exacerbates endothelial dysfunction in lupus mice. However, the specific impact of adenosine signaling on lupus-relevant vascular disease and neutrophil activity, as well as the role of adenosine receptors in APS, are heretofore unexplored. We now report that a specific adenosine receptor agonist attenuates aPL Ab-mediated NETosis in vitro and venous thrombosis in mice. Furthermore, the antithrombotic medication dipyrindamole phenocopies adenosine receptor agonism in terms of suppressing both NETosis and venous thrombosis.

Results

CAMP suppresses NETosis triggered by APS IgG. Antiphospholipid antibodies potentiate NETosis and thereby promote thrombotic events. Recent evidence suggests that the second messenger cAMP is amenable to pharmacologic manipulation, we reasoned that this might be an attractive pathway to target in APS neutrophils. 8-Br-cAMP is a cell-permeable, degradation-resistant analogue of cAMP. We found that treatment of neutrophils with 8-Br-cAMP mitigated the release of extracellular DNA (Sytox Green-positive signal, Fig. 1a) and NETs (Fig. 1b) by control neutrophils that were activated with IgG isolated and pooled from four primary APS patients (APS IgG). The clinical characteristics of these patients are described in Supplementary Table 1. PETosis was also assessed qualitatively by immunofluorescence microscopy with similar results (Fig. 1c). Given these data, we reasoned that similar suppression of NETosis should be achieved with activation of endogenous cAMP via the adenylyl cyclase activator forskolin. Indeed, the combination of forskolin and a phosphodiesterase 4 inhibitor mitigated NETosis (Fig. 1d). These data reinforce our hypothesis that manipulation of CAMP levels may be an effective way to mitigate NETosis in APS.

Agonism of the adenosine A2A receptor suppresses NETosis. As surface adenosine receptors are key regulators of neutrophil cAMP levels, we asked whether agonism of the adenosine A2A, A2B, or A3 receptor might regulate NETosis. An A2A agonist (CGS21680) suppressed APS IgG-mediated NETosis with nanomolar potency. In contrast, an A2B agonist (BAY60-6583) and an A3 agonist (2-Cl-IB-MECA) did not modulate NETosis (Fig. 2a-c), even at concentrations as high as 10 µM (Supplementary Fig. 1). A second A2A agonist (regadenoson/Lexiscan), which is approved for use in humans, was also tested, and resulted in similar suppression of NETosis (Supplementary Figure 2). Furthermore, suppression by CGS21680 was similarly effective when NETosis was activated by anti-β2GPI IgG that had been affinity-purified from the serum of an APS patient (Fig. 2d-e). To determine the extent to which CGS21680-mediated suppression required CAMP, we tested inhibitors of two key CAMP-dependent pathways in neutrophils: protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC). While an EPAC inhibitor had no effect on the ability of CGS21680 to suppress APS IgG-mediated NETosis, suppression was completely neutralized by a PKA inhibitor (Fig. 2f). In summary, these data demonstrate that the adenosine A2A receptor agonist CGS21680 suppresses NETosis triggered by APS patient antibodies, and that PKA is a downstream effector of this suppression.
Adenosine A2A receptor agonism suppresses ROS formation.

To understand the mechanism by which adenosine A2A receptor agonism mitigates NETosis, we asked whether inhibition would extend to NETosis activated by phorbol 12-myristate 13-acetate (PMA). Indeed, PMA-mediated NETosis was effectively suppressed by CGS21680 (Fig. 3a, b). PMA activates protein kinase C in neutrophils and in doing so triggers the assembly and activation of the NADPH oxidase complex, which is required for efficient NETosis in response to many stimuli23. As expected, PMA triggered the formation of H2O2 by neutrophils, which was suppressed by CGS21680 (Fig. 3c). These results were mirrored by APS IgG, with induction of H2O2 in neutrophils that could be suppressed by CGS21680 (Fig. 3d). In summary, these data reveal a potential mechanism by which CGS21680 suppresses NETosis, namely the suppression of NADPH oxidase-generated ROS.

Dipyridamole suppresses NETosis via adenosine A2A receptor.

The antithrombotic medication dipyridamole is known to potentiate adenosine receptor-mediated signaling by (i) increasing extracellular concentrations of adenosine, and (ii) interfering with the breakdown of cAMP24. Indeed, dipyridamole suppressed APS IgG-mediated NETosis (Fig. 4a, b), an effect which could be fully reversed with an A2A receptor antagonist (Fig. 4c, d). Consistent with its role as an antagonist of adenosine uptake into cells, we demonstrated that dipyridamole raised adenosine levels in culture supernatants (Fig. 4e). Beyond in vitro-activated neutrophils, we also found that dipyridamole suppressed the spontaneous NETosis of neutrophils freshly isolated from primary APS patients (Fig. 4f, g). Similar suppression was seen with CGS21680 and 8-Br-cAMP (Fig. 4f, g). The clinical characteristics of these patients are described in Supplementary Table 1. In summary, these data demonstrate that dipyridamole phenocopies CGS21680 by suppressing NET release from APS neutrophils via activation of the adenosine A2A receptor.

Adenosine A2A receptor agonism mitigates venous thrombosis.

Studies in humans have implicated neutrophils and NETs in pathologic thrombosis across various vascular beds25–27. At the same time, our group and others have proven a role for NETs in mouse models of venous thrombosis12,28,29. Here, we reasoned that CGS21680, which suppresses NETosis by human neutrophils in vitro, might also mitigate venous thrombosis in vivo. We first
demonstrated that CGS21680 reduced NETosis in murine neutrophils in vitro (Fig. 5a), similar to what we had observed in human neutrophils (Fig. 2a-c). Then, in a flow restriction model of inferior vena cava (IVC) thrombosis (Fig. 5b), we found that administration of CGS21680 not only reduced thrombus incidence, weight, and length (Fig. 5c-e), but also lowered plasma NET levels (Fig. 5f). Administration of CGS21680 did not affect the blood pressure or heart rate of treated mice (Supplementary Figure 3). Interestingly, CGS21680 was not effective in a different model of venous thrombosis (full-ligation/stasis)
that demonstrates less neutrophil dependence (Supplementary Fig. 4)\textsuperscript{30}. In summary, these data are the first to demonstrate the efficacy of an adenosine A\textsubscript{2A} receptor agonist against venous thrombosis.

**Dipyridamole suppresses NETosis and venous thrombosis.** We next asked whether dipyridamole would, similar to CGS21680, mitigate venous thrombosis and the formation of plasma NETs in the context of the flow-restriction model. Indeed, dipyridamole reduced thrombus weight, albeit without a statistically significant effect on incidence or length (Fig. 5g-i). Plasma NET levels were also significantly decreased when mice subjected to the flow-restriction model were treated with dipyridamole (Fig. 5j). In summary, dipyridamole suppresses NETosis and venous thrombosis in vivo.

**Adenosine A\textsubscript{2A} receptor agonism mitigates APS thrombosis.** In the flow-restriction model, we have previously demonstrated that the administration of IgG isolated from APS patients potentiates thrombosis\textsuperscript{12}. Here, we found that CGS21680 is highly effective in this APS model, reducing thrombus incidence, weight, and length (Fig. 6a-d). We next introduced a second model of IVC thrombosis to further examine APS-accelerated thrombosis in the context of active blood flow. In the electrolytic model (Fig. 6e), the application of mild direct electrical current results in the release of free radicals within the IVC, which activate endothelial cells and initiate a thrombogenic environment in the presence of constant blood flow\textsuperscript{31}. First we revealed that administration of APS IgG (isolated from individual patients), but not control IgG, potentiated thrombus size (Fig. 6f, g). Importantly, both thrombus size and NET release were reduced by treatment with intravenous deoxyribonuclease (DNase) (Fig. 6h, i). Going further, we found that both CGS21680 (Fig. 6j, k) and dipyridamole (Fig. 6l, m) functioned similarly to DNase, with no synergy appreciated between DNase and the A\textsubscript{2A} receptor agonists. In summary, these data are the first to demonstrate the efficacy of adenosine A\textsubscript{2A} receptor agonists against APS-accelerated venous thrombosis, with agonists functioning almost identically to DNase administration in the electrolytic model.

**Discussion**

APS is an autoimmune disorder that is primarily treated with anticoagulant, rather than immunomodulatory, medications.
While anticoagulation is somewhat effective against the thrombotic and pregnancy complications of APS, the approach comes with inherent and sometimes life-threatening complications, especially bleeding. Furthermore, anticoagulation has little proven efficacy in other APS manifestations such as cardiac valve disease, thrombocytopenia, nephropathy, cognitive decline, and seizures. While current clinical efforts are primarily focused on testing direct oral anticoagulants in APS patients\(^\text{32}\), we would argue that better understanding the inflammatory pathophysiology of APS must continue to be emphasized, with the goal of establishing more targeted and effective therapeutics. Here, we demonstrate that a specific adenosine A\(_{2A}\) receptor agonist can attenuate APS IgG-mediated NETosis in vitro and venous thrombosis in mice. Furthermore, dipyridamole (an FDA-approved drug known

**Fig. 4** Dipyridamole suppresses NETosis via activation of the adenosine A\(_{2A}\) receptor. a, b Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG for 3 h. Some samples were additionally treated with dipyridamole as indicated. In panel a, total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b, an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for \(n = 3\) independent experiments; \(^*p < 0.05\), \(^**p < 0.01\), and \(^***p < 0.001\) as compared with the 0 \(\mu\)M group by one-way ANOVA corrected with Dunnett’s test. c, d Neutrophils were treated with APS IgG in the presence of different combinations of dipyridamole and the A\(_{2A}\) receptor antagonist SCH58261. Extracellular DNA (c) or NETs (d) were quantified as above. Mean and standard deviation are presented for \(n = 3\) independent experiments; \(^*p < 0.05\) and \(^**p < 0.01\) by one-way ANOVA. e Neutrophils were treated with APS IgG (black bars) and dipyridamole as indicated. Adenosine was quantified in culture supernatants. Mean and standard deviation are presented for \(n = 4\) independent experiments; \(^*p < 0.05\) by one-way ANOVA corrected with Sidak’s test. f, g Neutrophils were isolated from patients with primary APS and immediately placed in culture. Some samples were additionally treated with drugs as indicated. Extracellular DNA (f) or NETs (g) were quantified as above. Mean and standard deviation are presented for \(n = 9\) patients; \(^**p < 0.01\) and \(^***p < 0.001\) as compared with the no-drug group by one-way ANOVA corrected with Dunnett’s test.
to potentiate adenosine signaling) phenocopies adenosine A$_2A$ receptor agonism in terms of suppressing both NETosis and venous thrombosis.

Despite the abundance of neutrophils in peripheral blood (and their increasingly recognized role in pathological thrombosis), three other cell types—monocytes, endothelial cells, and platelets—have historically received more attention as drivers of thrombosis in APS. This work has demonstrated that anti-phospholipid antibodies actually engage phospholipid-binding proteins such as β$_3$GPI, which are found in association with cell-surface phospholipids. These interactions lead to cell activation and upregulation of prothrombotic molecules, including tissue factor, a potent mediator of thrombosis. More recently, our group and others have suggested a role for neutrophils in the prothrombotic diathesis inherent to APS. These studies were triggered by an emerging emphasis in the thrombosis literature regarding the importance of neutrophils, their heterotypic cell–cell interactions, and NETs in pathologic clotting—and, in particular, venous thrombosis. As examples, histones stimulate platelets; the DNA component of NETs activates the intrinsic coagulation cascade; and NET-derived proteases inactivate certain anticoagulant factors. In some contexts, NETs may also be an important source of tissue factor.

Our recent transcriptomic profiling of APS neutrophils revealed an activated signature with upregulation of complement and Fc receptors, selectins and their ligands, and interferon-
responsive pathways, among other genes\textsuperscript{13}. Pathway analysis demonstrated upregulation of three subunits of PKA in a node associated with metabolic processes: specifically two PKA catalytic subunits (PRKACA and PRKACG) and one PKA regulatory subunit (PRKAR1A)\textsuperscript{13}. This upregulation would seem to support PKA activation as a potential therapeutic strategy in APS (for example, with drugs such as phosphodiesterase 4 inhibitors)\textsuperscript{44}. Regarding mechanism, the PKA pathway has been shown to downregulate the phosphorylation of the p47 subunit of NADPH oxidase, which prevents its translocation to the membrane for assembly and activation with other subunits\textsuperscript{45}. Indeed, it is interesting that inhibition of PKA seems to activate NETosis in resting control neutrophils (Fig. 2f). Further studies should explore the extent to which cAMP/PKA functions as a homeostatic pathway that keeps NETosis at bay, perhaps especially in adherent neutrophils. It may also be interesting to determine the extent to which the cAMP/PKA axis can counterbalance signaling through surface receptors such as the C5a receptor, which our
previous work has revealed to be upregulated in APS neutrophils.\textsuperscript{13} For in vivo studies, it is possible (if not likely) that agonism of the adenosine A\textsubscript{2A} receptor has antithrombotic properties that extend beyond suppression of NETosis—properties which may take on increased importance depending on which vascular bed is being studied. For example, beyond neutrophils, platelets express the A\textsubscript{2A} receptor, which suppresses platelet aggregation when activated\textsuperscript{46}, an effect that may be especially relevant in the context of arterial thrombosis. In the data presented here, we find that both CGS21680 and dipyridamole are highly effective against APS IgG-accelerated venous thrombosis, reducing thrombus size to the levels seen in control mice (these data are essentially indistinguishable from what we see when mice are treated with systemic DNase). Given that all three treatments (CGS21680, dipyridamole, and DNase) reduce plasma levels of NETs in similar fashion, and given that we do not see synergy when combining treatments (for example, CGS21680 and DNase), we suspect that both CGS21680 and dipyridamole are acting primarily through neutrophil inhibition in these models. Going forward, this question may be additionally interrogated via the development of transgenic mice lacking the A\textsubscript{2A} receptor. Such mice could be used to further define thrombosis in large veins, while also asking questions about the role the neutrophil A\textsubscript{2A} receptor plays in other vascular beds. Indeed, our group and others have proposed that different cell types likely take on a different level of importance in APS depending on the vascular bed in question. As such, a drug with pleomorphic antithrombotic effects such as dipyridamole might be especially attractive for use in such patients.\textsuperscript{47} All mouse studies were performed in male mice given the more consistent surgical result in our hands (which we attribute to more consistent IVC anatomy). While many APS cohorts include more females than males (given associations of APS with pregnancy morbidity and female-predominant lupus)\textsuperscript{38}, the sex distribution is relatively equal between females and males when one considers primary thrombotic APS\textsuperscript{38}—which we consider the clinical framework for the data presented here. Of course, one might ask whether A\textsubscript{2A} receptor agonism would benefit other manifestations of APS beyond thrombosis such as pregnancy loss. While dipyridamole has a relatively robust safety record in pregnancy\textsuperscript{49}, we would consider such discussions premature, especially given that obstetric APS may have very different pathophysiology from thrombotic APS.\textsuperscript{50} Dipyridamole is known to potentiate adenosine receptor-mediated signaling by both increasing extracellular concentrations of adenosine and inhibiting phosphodiesterases that degrade cAMP.\textsuperscript{24} Unlike regadenoson (Supplementary Fig. 2), which has a short half-life in vivo and would require administration by infusion\textsuperscript{51,52}, dipyridamole has a profile compatible with long-term administration\textsuperscript{53}. While dipyridamole has never been systematically tested in patients with APS, drugs with similar adenosine-amplifying properties, such as dilazep\textsuperscript{54} and defibrotide\textsuperscript{55}, have been reported as effective in either case reports or preclinical models. The data presented here suggest the potential for an anti-inflammatory therapeutic paradigm in APS, which may even extend to selected cases of venous thrombotic disease in the general population.

**Methods**

**Purification of patient IgG.** This study complied with all relevant ethical regulations and was approved by the University of Michigan Institutional Review Board; all participants provided informed consent for blood donation. IgG was purified from APS or control sera with a Protein G Agarose Kit following the manufacturer’s instructions (Pierce). Briefly, serum was diluted in IgG binding buffer and passed through a Protein G Agarose column at least five times. IgG was then eluted with 0.1 M glycine and then neutralized with 1 M Tris. This was followed by overnight dialysis against PBS at 4 °C. IgG purity was verified with Coomassie staining, and concentrations were determined by BCA protein assay (Pierce) according to manufacturer’s instructions. All IgG samples were determined to be free of detectable endotoxin by the Pierce LAL Chromogenic Endotoxin Quantitation Kit (88282) according to manufacturer’s instructions.

**Human neutrophil purification and NETosis assays.** For neutrophil purification, blood from either healthy volunteers or APS patients was collected into heparin tubes by standard phlebotomy techniques. The anticoagulated blood was then fractionated by density-gradient centrifugation using Ficoll-Paque Plus (GE Healthcare). Neutrophils were further purified by dextran sedimentation of the red blood cell layer, before lysing residual red blood cells with 0.2% sodium chloride. Neutrophil preparations were at least 95% pure as con

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09801-x | www.nature.com/naturecommunications
single data point. All experiments were performed at least three times (i.e., independent experiments on three separate days).

For preparation of NET-associated myeloperoxidase (MPO) assay, neutrophils were cultured as above in 96-well plates. To collect NET-associated MPO, the culture media was discarded (to remove any soluble MPO) and replaced with 100 µL of RPMI supplemented with 5 U ml

−1 mix. After 10 min at 37 °C, digestion of NETs was stopped with 10 µM EDTA. Supernatants were then transferred into a new plate. To measure for MPO activity, an equal volume of 3,3',5,5'-Tetramethylbenzidine (TMB) substrate (1 mg ml

−1, Sigma-Aldrich) was added to each well. After 10 min of incubation in the dark, the reaction was stopped by the addition of 50 µL of 1 M sulfuric acid. Absorbance was measured at 450 nm using a Cytoflex 5 Cell Imaging Multi-Mode Reader.

For immunofluorescence microscopy, 1.5 × 10

5 neutrophils were seeded onto cover slips coated with 0.001% poly-l-lysine (Sigma) and fixed with 4% paraformaldehyde. In some experiments, cells were then permeabilized with 0.1% Triton-X for 15 min at 4 °C. Immunofluorescence staining was with 1% bovine serum albumin. The primary antibody was against neutrophil elastase (Abcam 21595, diluted 1:100), and the FITC-conjugated secondary antibody was from Invitrogen. Images were collected with a Cytation 5 Cell Imaging Multi-Mode Reader.

**Purification of β2GPI and IgG anti-β2GPI.** β2GPI was isolated from pooled human serum (Innovative Research) as described previously56, with slight modifications. Briefly, 500 mL of human serum was diluted with an equal volume of normal saline, followed by treatment with 6% paraldehyde (Sigma) at 4 °C to a final concentration of 0.285 M. The mixture was stirred for 15 min at 4 °C, and the supernatant was then centrifuged at 4500 × g for 15 min at 4 °C. The supernatant pH was adjusted to 8.0 and was dialyzed against 0.02 M NaCl + 0.03 M Tris pH 8.0 overnight at 4 °C. β2GPI was then purified using a HiTrap Heparin column (GE Healthcare) in an AKTA Prime chromatographic system (GE Healthcare) at 4 °C. The adsorbed protein was eluted stepwise with 0.02 M Tris buffer pH 8.0 with increasing mole fraction of NaCl (0.03, 0.15, and 0.3 M). The fractions eluted with 0.035 M NaCl were pooled and dialyzed overnight against 0.05 M sodium acetate, and the fractions that were then further purified using Resource S columns (GE Healthcare). Elutes were collected with a 0–100% gradient from 0.05 M sodium acetate pH 4.8 + 0.05 M NaCl to 0.05 M sodium acetate pH 5.2 + 0.65 M NaCl. Protein fractions were identified by SDS PAGE, pooled, and dialyzed overnight against PBS at 4 °C.

**H2O2 assay.** The generation of H2O2 was quantified, essentially as described previously57. Briefly, H2O2 production was detected by a colorimetric assay, with 50 µM Amplex Red reagent (Invitrogen) and 10 U ml

−1 horseradish peroxidase (Sigma) added to the culture medium. Absorbance was measured at 560 nm and linearity was assured with an H2O2 standard curve.

**Animal housing and treatments.** Mice were housed in a specific pathogen-free barrier facility, and fed standard chow. Experimental procedures were approved by the University of Michigan Institutional Animal Care and Use Committee, and all relevant ethical regulations were followed. Male C57BL/6 mice were purchased from The Jackson Laboratory. GCS21680 (Tocris Bioscience) was administered by intraperitoneal injection, 0.5 mg kg

−1 twice daily. Pharmaceutical-grade diprydiamole (NDC 0641-2569-44) was administered by intraperitoneal injection (5 mg kg

−1). Some mice were additionally administered DNase (Pulmozyme/dornase alfa, Genentech) every 12 h: 50 µg by intraperitoneal injection and 10 µg by intravenous (retro-orbital) injection with each therapy. Therapy was always started one day prior to IVC clotting, and continued through the duration of the experiment.

**Mouse neutrophil purification and NETosis assay.** Bone marrow neutrophils were isolated according to our usual protocol.8,24 Total bone marrow cells were spun on a discontinuous Percoll gradient (52%–69%–78%) at 1500 × g for 30 min. Cells from the 69–78% interface were collected. These cells were >95% Ly-6G-positive by flow cytometry, and had typical nuclear morphology by microscopy. To assess in vitro NETosis, a protocol similar to what we have described previously was followed.56 Culture was for 4 h at 37 °C in RPMI media supplemented with 2% bovine serum albumin and 10 mM HEPES buffer. Stimulation was with control IgG or APS IgG at a concentration of 10 µg ml

−1. For immunofluorescence, cells were fixed with 4% paraformaldehyde. DNA was stained with Hoechst 33342 (Invitrogen), while protein staining was with rabbit anti-citrullinated histone H3 (Abcam 5103, diluted 1:100), followed by FITC-conjugated anti-rabbit IgG (SouthernBiotech 4052-02, diluted 1:250). Images were collected with a Cytation 5 Cell Imaging Multi-Mode Reader. NETs (decondensed extracellular DNA co-staining with citrullinated histone H3) were quantified by blinded observers, and digitally recorded to prevent multiple counts. The percentage of NETs was calculated after counting 10 200x fields per sample52.

**In vivo venous thrombosis.** To model large-vein thrombosis, we employed procedures that we have utilized previously21,23. For the stenosis model, male C57BL/6 wild-type mice were administered two doses (500 µg each) of either control or APS IgG by intraperitoneal injection, 48 h apart. Prior to the second injection, a laparotomy was performed under anesthesia, and a ligature was fastened around the IVC over a blunted 30-gauge needle (which served as a spacer); side and back branches were then manipulated with the needle. The needle was closed, and the mouse was allowed to recover. In separate experiments to examine complete stasis, the IVC was fully ligated, without use of a spacer, and all visible side and back branches were also ligated. Mice were humanely euthanized and thrombus formation was assessed 48 h after laparotomy.

**Blood pressure.** Non-invasive blood pressure was measured by tail cuff as described58. Briefly, using the IITC Life Science blood pressure measurement system, conscious and restrained mice were acclimated for 3 days in a temperature-controlled environment (model 306 warming chamber). The tail vein was occluded with an integrated sensor-cuff (model I-B60-1/4) and return of pulsation (RTP) detected by the RTP-computerized blood pressure monitor (model 6 M 229 6 channel mouse system). Repeated measures were averaged for determination and report of systolic blood pressure and heart rate.

**Measurement of adenosine levels in culture supernatants.** Neutrophils (2 × 10

5) were incubated in 12-well plates at 37 °C with 10 µg ml

−1 APS IgG in the presence or absence of dipyridamole (10 µM). After 3 h, 1-ml supernatants were collected and centrifuged at 9000 × g for 5 min to remove insoluble particles. Supernatants were assayed without dilution via the Adenosine Assay Kit MET-5090 (Cell Biologics, Inc) according to the manufacturer’s instructions.

**Statistical analysis.** Data analysis was with GraphPad Prism software version 8. For continuous variables, group means were compared by either t-test (two groups) or one-way ANOVA (more than two groups); correction for multiple comparisons was by Dunn’s method. For categorical variables, analysis was by Chi-square test. Statistical significance was defined as p < 0.05.
2. Cervera, R. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis Rheum.* 46, 1019–1027 (2002).
3. Gomez-Puerta, J. A. & Cervera, R. Diagnosis and classification of the antiphospholipid syndrome. *J. Autoimmun.* 48–49, 20–25 (2014).
4. Abreu, M. M. et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. *Autoimmun. Rev.* 14, 401–414 (2015).
5. Erkan, D. et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. *Autoimmun. Rev.* 13, 685–696 (2014).
6. Conti, F. et al. Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression. *Clin. Exp. Immunol.* 132, 509–516 (2003).
7. Caronti, B. et al. Beta2-glycoprotein I (β2GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. *Clin. Exp. Immunol.* 115, 214–219 (1999).
8. Ma, K. et al. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. *J. Biol. Chem.* 275, 15541–15548 (2000).
9. Allen, K. L. et al. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. *Blood* 119, 884–893 (2012).
10. Soric, M. et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. *Arthritis Rheum.* 56, 2687–2697 (2007).
11. Yalavathri, S. et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. *Arthritis Rheum.* 67, 2990–3003 (2015).
12. Meng, H. et al. In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis. *Arthritis Rheum.* 69, 655–667 (2017).
13. Knight, J. S. et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. *JCI Insight* https://doi.org/10.1172/jci.insight.93897 (2017).
14. Eby, J. C., Gray, M. C. & Hewlett, E. L. Cyclic AMP-mediated suppression of neutrophil extracellular trap formation and apoptosis by the Bordetella pertussis adenylate cyclase toxin. *Infect. Immun.* 82, 5256–5269 (2014).
15. Shishikura, K. et al. Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP. *Br. J. Pharm.* 173, 319–331 (2016).
16. Cronstein, B. N. & Sitkovsky, M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. *Nat. Rev. Rheumatol.* 13, 41–51 (2017).
17. Barletta, K. E., Ley, K. & Mehrad, B. Regulation of neutrophil function by adenosine. *Arterioscler. Thromb. Vasc. Biol.* 32, 856–864 (2012).
18. Cronstein, B. N., Kramer, S. B., Weissmann, G. & Hirschhorn, R. Adenosine: a physiological modulator of superoxide anion generation by human monocytes. *J. Exp. Med.* 158, 1160–1177 (1983).
19. van der Hoeven, D., Wan, T. C. & Auchampach, J. A. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. *Mol. Pharm.* 74, 685–696 (2008).
20. Zhang, L. et al. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. *Lupus* 20, 667–677 (2011).
21. Knight, J. S. et al. Ectonucleotidase-mediated suppression of lupus autoimmunity and vascular dysfunction. *Front Immunol.* 9, 1322 (2018).
22. Hasko, G., Linden, J., Cronstein, B. & Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat. Rev. Drug Discov.* 7, 759–770 (2008).
23. Steiber, W., Obermayer, A., Steinbacher, P. & Krautgartner, W. D. The role of reactive oxygen species (ROS) in the formation of extracellular traps (ETs) in humans. *Biomolecules* 5, 702–723 (2015).
24. Balakumar, P. et al. Classical and pleiotropic actions of dipridamole: not enough light to illuminate the dark tunnel? *Pharm. Res.* 37, 144–150 (2014).
25. Doring, Y., Soehnlein, O. & Weber, C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. *Circ. Res.* 120, 736–743 (2017).
26. Martinod, K. & Wagner, D. D. Thrombosis tangled up in NETs. *Blood* 123, 2768–2776 (2014).
27. Matevosyan, K. & Sarode, R. Thrombosis, microangiopathies, and inflammation. *Semin. Thromb. Hemost.* 41, 556–562 (2015).
28. von Bruhl, M. L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice. *J. Exp. Med.* 209, 819–835 (2012).
29. Martinod, K. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. *Proc. Natl Acad. Sci. USA* 110, 8674–8679 (2013).
30. El-Sayed, O. M. et al. Intact Toll-like receptor 9 signaling in neutrophils modulates normal thrombogenesis in mice. *J. Vasc. Surg.* 64, 1450–1460 (2016).
31. Palmer, O. R. et al. Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis. *Res. Pr. Thromb. Haemost.* 2, 266–273 (2018).
32. Cronstein, B. N., Caron, R. & Pacher, P. Adenosine: a physiological modulator of superoxide anion generation by human monocytes. *J. Exp. Med.* 158, 1160–1177 (1983).
33. van der Hoeven, D., Wan, T. C. & Auchampach, J. A. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. *Mol. Pharm.* 74, 685–696 (2008).
34. Zhang, L. et al. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. *Lupus* 20, 667–677 (2011).
35. Knight, J. S. et al. Ectonucleotidase-mediated suppression of lupus autoimmunity and vascular dysfunction. *Front Immunol.* 9, 1322 (2018).
Acknowledgements

R.A.A. was supported by NIH T32AR007080. J.S.K. was supported by career development awards from the NIH (K08AR066569) and Burroughs Wellcome Fund.
Y.K. was supported by NIH R01HL131993 and L30HL129373. The work was primarily supported by NIH R01HL134846 to J.S.K. The work was also supported by R01HL127151 to D.J.P. We thank the University of Michigan Cardiovascular Physiology Phenotyping Core for expert technical assistance. The University of Michigan Physiology Phenotyping Core was supported by grant funding from the NIH (OD016502), the Department of Molecular and Integrative Physiology, and the Frankel Cardiovascular Center.

Author contributions

R.A.A., A.A.G., H.M., S.Y., A.P.V., S.K.E. and O.R.P. conducted experiments and analyzed data. R.A.A., P.L.B., D.J.P., J.M.G., J.A.D., Y.K. and J.S.K. designed the study and analyzed data. All authors participated in writing the manuscript, and gave approval before submission.

Additional information

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-019-09801-x.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Journal peer review information: Nature Communications thanks Kimberly Martinod and other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2019